Gamma Therapeutics is categorized under Commercial Medical Research in Portland, OR and active since 2009.
Gamma Therapeutics was established in 2009, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 6213400 by the NAICS.
If you are seeking more information, feel free to contact David F Eastman at the company’s single location by writing to 2611 Sw 3rd Avenue, Portland, Oregon OR 97201 or by phoning (503) 222-2306. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Gamma Therapeutics |
| Contact Person: | David F Eastman |
| Address: | 2611 Sw 3rd Avenue, Portland, Oregon 97201 |
| Phone Number: | (503) 222-2306 |
| Website Address: | 13therapeutics.com |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2009 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 6213400 |
| Share This Business: |
Gamma Therapeutics was started in 2009 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 6213400. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact David F Eastman for inquiries that concern Gamma Therapeutics by calling the company number (503) 222-2306, as your correspondence is most welcome. Additionally, the physical location of the single location of Gamma Therapeutics can be found at the coordinates 45.504341,-122.68092 as well as the street address 2611 Sw 3rd Avenue in Portland, Oregon 97201.
For its online presence, you may visit Gamma Therapeutics’s website at 13therapeutics.com and engage with its social media outlets through on Twitter and on Facebook.